Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- Jun 4
- 3 min read
03/06/2026
Johnson & Johnson late-breaking results showed nipocalimab significantly reduced SLE disease activity in a Phase 2 study (Ref)
Johnson & Johnson announced that the Phase 2, JASMINE/ NCT04882878 study which evaluated nipocalimab (FcRn blocker) in adults with moderate-to-severe systemic lupus erythematosus (SLE).
The trial met its primary endpoint of decreasing disease activity at 24 weeks as measured by SRI-4 and continued to demonstrate sustained reduction in disease activity in adults with moderate-to-severe SLE through 52 weeks.
These Phase 2 results will be featured in late-breaking presentations at EULAR-2026 Congress.
The ongoing Phase 3 study of nipocalimab was currently recruiting people living with SLE.
Johnson & Johnson announced biomarker exploratory analyses from a Phase 2 study of nipocalimab in moderate-to-severe SjD (Ref)
Johnson & Johnson announced new biomarker exploratory analyses from the Phase 2, DAHLIAS/ NCT04968912 study of nipocalimab (FcRn blocker) in adults with moderate-to-severe Sjögren's disease (SjD)
In the analysis, patients in the autoantibody-high subgroup treated with nipocalimab achieved higher response rates than observed in the overall participant population (62.5% versus 51.9%).
These data were presented in an oral session at the EULAR -2026 Congress.
Argenx presented efgartigimod data showing long-term sustained patient benefit in myositis and SjD at EULAR-2026 (Ref)
Argenx announced the presentation of new data evaluating VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) across autoimmune rheumatic diseases, including myositis and Sjogren’s disease that were presented at the EULAR 2026 Congress.
ALKIVIA+/ NCT05979441 data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements.
The safety profile was consistent over the course of the study, with no increase in adverse events with longer exposure.
RHO+ data in Sjogren’s disease indicate maintenance of response following switch to biweekly dosing.
Efgartigimod was well tolerated, with no new safety signals identified following long-term use in participants with Sjogren’s disease.
JJP Biologics announces positive interim Phase 1b data for nebaprubart in Linear IgA Disease (Ref)
JJP Biologics announced positive interim data from its ongoing Phase 1b trial evaluating nebaprubart (JJP-1212; anti-CD89 antagonist) in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.
Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed in patients with LAD.
Data supported the start of a Phase 1b clinical trial in rheumatoid arthritis, anticipated in Q3 2026.
Spyre Therapeutics announced completion of enrolment in basket trial evaluating SPY072 in RA, PsA and axSpA (Ref)
Spyre Therapeutics announced the completion of enrollment for all sub-studies in the SKYWAY basket trial of SPY072 (anti-TL1A) in rheumatic diseases (psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA)).
Company reiterated the expected Q3 2026 readout for RA and Q4 2026 readouts for PsA and axSpA.
Across the SKYWAY and SKYLINE trials, planned 6 in 26 Phase 2 readouts enabled and on track.
Preclinical data supporting SPY072 in rheumatic diseases were presented at EULAR-2026 congress.
MannKind announced completion of randomization in the Phase 1b trial and enrollment of the first patient in Phase 2 trial for nintedanib DPI in patients with IPF (Ref)
MannKind Corporation announced clinical execution milestones in the development of nintedanib DPI for idiopathic pulmonary fibrosis (IPF), including the completion of patient randomization in the US Phase 1b, INFLO-1/ NCT07344558 trial and enrollment of the first patient in the global Phase 2, INFLO-2 study.
MannKind expected to report data from the INFLO-1 study in Q3 2026.
INFLO-2 was expected to enroll approximately 210 participants across approximately 85 sites worldwide, the first patient was enrolled in Windsor, Canada.
